Johnson & Johnson (JNJ) Updates FY17 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) updated its FY17 earnings guidance on Thursday. The company provided earnings per share guidance of $7.25 – $7.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.28.

Several brokerages have recently weighed in on JNJ. Vetr upgraded shares of Johnson & Johnson from a hold rating to a buy rating and set a $147.14 price objective on the stock in a report on Wednesday. Zacks Investment Research lowered shares of Johnson & Johnson from a buy rating to a hold rating in a report on Tuesday, December 12th. Citigroup began coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They set a neutral rating and a $140.00 price objective on the stock. BMO Capital Markets restated a positive rating and issued a $152.00 target price (up previously from $145.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Finally, Jefferies Group upped their target price on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a buy rating in a report on Monday, October 16th. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of Hold and a consensus target price of $145.51.

Johnson & Johnson (NYSE:JNJ) traded down $0.10 on Thursday, hitting $141.06. 5,501,307 shares of the company were exchanged, compared to its average volume of 5,901,215. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35. The firm has a market cap of $378,960.00, a price-to-earnings ratio of 19.86, a PEG ratio of 2.88 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the firm posted $1.68 EPS. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.

A number of hedge funds have recently modified their holdings of the business. Landmark Financial Advisors LLC grew its position in Johnson & Johnson by 0.4% in the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after purchasing an additional 7 shares in the last quarter. Premier Asset Management LLC grew its position in Johnson & Johnson by 0.4% in the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares in the last quarter. Lbmc Investment Advisors LLC grew its position in Johnson & Johnson by 0.4% in the 2nd quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after purchasing an additional 14 shares in the last quarter. Halbert Hargrove Russell LLC grew its position in Johnson & Johnson by 0.4% in the 2nd quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after purchasing an additional 15 shares in the last quarter. Finally, Lenox Wealth Management Inc. grew its position in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after purchasing an additional 24 shares in the last quarter. 65.70% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Updates FY17 Earnings Guidance” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/21/johnson-johnson-jnj-updates-fy17-earnings-guidance.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit